Overview of Liracol

Quick Facts

Property	Description
Active Ingredients	Nifuroxazide, Phthalylsulfathiazole
Form	Oral Tablet or Capsule
Pharmacological Class	Intestinal Anti-infective (Nitrofuran & Sulfonamide)
General Purpose	Managing bacterial-induced intestinal disturbances
Origin	Synthetic Organic Compound

What Type of Medicine is Liracol?

Liracol is a combination product classified as an Intestinal Anti-infective, a specialized medication designed for oral administration and targeted action within the gastrointestinal tract. This fixed-dose entity contains two distinct synthetic organic compounds: Nifuroxazide and Phthalylsulfathiazole. The Intestinal Anti-infective classification defines its role in combating infections localized in the gut. Liracol is particularly characterized by its negligible systemic absorption, focusing its antimicrobial activity primarily within the gut lumen. This design is strategically utilized in clinical settings when localized microbial control is required, making it distinct from highly absorbed systemic antibiotics.

Composition and Purpose: The Role of Nifuroxazide and Phthalylsulfathiazole

Liracol leverages the synergistic relationship of its two core components, which stem from different pharmacological classes, to achieve a broad-spectrum effect utilized for managing various bacterial-induced gut disturbances. Nifuroxazide is a Nitrofuran antibacterial, and Phthalylsulfathiazole is a prodrug belonging to the Sulfonamide antibacterial class, contributing to the overall broad-spectrum capability. Phthalylsulfathiazole functions by releasing its active component in the gut to exert a bacteriostatic effect by blocking the bacterial synthesis of folic acid. The general purpose of this specific dual composition is to efficiently help manage acute intestinal disturbances, such as general travelers' diarrhea, by employing these two distinct mechanisms against pathogenic bacteria, thereby addressing the microbiological source of the disruption within the gastrointestinal tract and providing comprehensive antimicrobial activity.

What side effects are possible with Liracol?

The official safety profile for Liracol, a combination of Nifuroxazide and Phthalylsulfathiazole, is structured around the adverse reactions documented for its two distinct active components in regulatory sources. Reactions are formally classified by frequency and grouped into System-Organ Classes (SOCs) according to established regulatory standards.

Adverse Reaction Scope

Classification Domain	Key Components as Documented in Official Labels
Frequency Classification	Adverse reactions are assigned categories of Common, Uncommon, or Rare, and Frequency Not Known (for post-marketing events lacking incidence data).
System-Organ Classes	Effects are grouped primarily into Gastrointestinal disorders (e.g., nausea, abdominal pain), Skin and Subcutaneous Tissue disorders (e.g., rash, pruritus), and Immune System disorders (hypersensitivity).
Serious Adverse Reactions	Officially documented severe risks associated with the components include Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, and potentially fatal Hematological Disorders (e.g., Agranulocytosis).

Safety Constraints and Restrictions

Official labeling defines specific conditions and patient groups where the use of this medicine is restricted:

Population-Specific Constraints: Regulatory bodies advise that the product should not be used during Pregnancy and Breastfeeding due to safety concerns, including a documented possible mutagenic potential for Nifuroxazide.
Absolute Restrictions: The medicine is formally contraindicated in individuals with a known Hypersensitivity to Nifuroxazide, Phthalylsulfathiazole, or any excipient. It is also restricted in individuals with Severe Hepatic Impairment or a history of Biliary Disease.

Connection to the Overall Safety Profile

The regulatory safety information establishes a profile that differentiates between expected, common effects, such as gastrointestinal disturbances, and the rare, serious systemic risks associated with the Sulfonamide component. This official classification ensures that the full range of potential outcomes, from mild effects to severe cutaneous and blood disorders, is formally documented and used to define the safety constraints on the medicine's use.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation requires that immediate medical attention be sought following suspected over-ingestion of Liracol (Nifuroxazide, Phthalylsulfathiazole). Patients must contact emergency services immediately if severe or life-threatening manifestations are observed.

Overdose presentations are primarily defined by the potential for systemic toxicity from the components, despite the drug's localized intestinal action. Documented manifestations may include severe gastrointestinal distress such as vomiting and diarrhea. Severe outcomes listed in regulatory documents include Acute Kidney Injury from crystalluria and serious Blood Dyscrasias (e.g., agranulocytosis), along with the potential for peripheral neuropathy.

Overdose Component	Regulatory Note
Antidote Availability	No specific antidote is known.
Management	Treatment is strictly symptomatic and supportive.
Monitoring Required	Specific monitoring of renal function and hematological monitoring are mandated procedures.

Increased risk and severity are documented for individuals with pre-existing renal impairment and those with G6PD deficiency. The official guidance specifies that hospital monitoring may be required to observe and manage potential organ damage.

Therapeutic Uses of Liracol

Liracol is applied in areas where short-term symptom management is appropriate, used in situations involving certain distressing symptoms. It is applicable within clinical settings that involve acute or disruptive symptom patterns. The general therapeutic uses of this class of medication include the management of symptoms associated with temporary physical distress.

Liracol is relevant in conditions characterized by episodic or fluctuating manifestations where supportive symptomatic assistance is needed. It is commonly used across conditions presenting with systemic or localized discomfort and those associated with acute or episodic changes. These uses are relevant for easing symptoms related to physical discomfort, systemic imbalance, and inflammatory or irritative states, such as general pain and aches, fever, and localized swelling.

“The medication supports the patient during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms.”

Quick Fact: Relevant for Symptomatic Relief in the domains of Aches, Fever, and Swelling

Managing Symptomatic Relief

Liracol is applied in addressing symptoms that interfere with routine activities, such as headaches and muscle aches. It is generally relevant in contexts involving heightened systemic burden, specifically applied in addressing symptoms related to systemic imbalance, such as fever. This assists with managing symptoms that create noticeable physiological strain and supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Liracol — Official Regulatory Information

The official eligibility profile for Liracol, a combination intestinal anti-infective containing Nifuroxazide and Phthalylsulfathiazole, is defined by specific exclusions and restrictions documented by regulatory authorities.

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults (18 years and older) who present within the official labeled indication.
Populations for whom use is contraindicated	Patients with known hypersensitivity to Sulfonamide or Nitrofuran derivatives. Newborns/Infants (typically under 1 or 2 months) due to the risk of hemolytic anemia. Individuals with Severe Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency or intestinal obstruction.
Age-related eligibility rules	Newborns are absolutely prohibited from using the medicine. Pediatric use is generally not recommended below specific age thresholds established by regional authorities.
Condition-specific eligibility rules	Use requires caution or restriction in cases of severe renal impairment or severe hepatic impairment. Contraindicated in patients with a history of acute porphyria.
Pregnancy and lactation eligibility status	Use is not recommended or avoided during pregnancy and lactation as a standard precautionary measure.

Regulatory documents establish these constraints primarily through absolute contraindications—such as G6PD deficiency and use in newborns—and restrictions on use in vulnerable groups, including those with organ impairment or during reproductive periods. This structure precisely defines the population limits for Liracol as mandated by official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Liracol

The documented interaction profile for Liracol (Nifuroxazide and Phthalylsulfathiazole) is primarily structured around pharmacodynamic effects and local absorption interference, consistent with its negligible systemic absorption.

Interaction scope

Category	Official Regulatory Information
Medicinal product categories with documented interactions:	Sulfonylureas, Bile Acid Sequestrants, highly Plasma Protein-Bound Drugs, Systemic Anti-Infectives, Antimetabolites.
Specific interacting medicines (if explicitly listed):	Insulin, Methotrexate, Cholestyramine, Colestipol, Benzylpenicillin, Warfarin (as a representative highly protein-bound agent).
Mechanistic basis of interactions (only if stated in label):	Pharmacodynamic interaction (additive effects); Local Absorption Interference; Competition for Plasma Protein Binding Sites; Altered Excretion Rate.
Timing-based interaction rules (if applicable):	Interference with absorption by Bile Acid Sequestrants implies a regulatory requirement for timing separation of doses to mitigate a reduction in serum concentration.
Population-specific interaction notes (if applicable):	Pharmacokinetics in patients with compromised renal or hepatic function have not been studied, a factor that requires regulatory caution regarding interaction risk in these populations.

Interaction classifications (high-level)

Category	Official Regulatory Statement
Interaction severity classification (as defined in official documents):	Classified as generally requiring Caution and Monitoring for pharmacodynamic and exposure-altering effects.
Regulatory basis (EMA / FDA / etc.):	Information is based on official prescribing documents for the two active components, referencing the Sulfonamide and Nitrofuran pharmacological classes.

Resulting interaction structure

Official interaction statements:

Co-administration with Insulin or Sulfonylureas is associated with an increased risk of hypoglycemia.
Cholestyramine and Colestipol cause Local Absorption Interference, leading to a reduced serum concentration of Phthalylsulfathiazole.
Phthalylsulfathiazole may increase the protein binding of Methotrexate and decrease the excretion rate of Benzylpenicillin.
Regulatory information states there is no significant inhibitory effect on cytochrome P450 enzymes documented for Liracol's components.

Connection to the overall interaction profile (2–4 sentences):

Regulatory documents define this product's interaction structure primarily through the risk of pharmacodynamic reinforcement with antidiabetic agents, and documented effects on local and systemic exposure of co-administered medications. This profile is consistent with a dual-component drug designed for highly localized intestinal action, focusing regulatory scrutiny on specific absorption and clearance constraints.

Mechanism of Action

Liracol is a proprietary formulation containing Nifuroxazide and Attapulgite.

The mechanistic action of Nifuroxazide is initiated by its selective accumulation within susceptible bacterial cells. Once internalized, this nitrofuran derivative undergoes nitro-reduction, generating reactive nitro radicals. These highly reactive species serve as non-specific antagonists by covalently binding to, and damaging, critical bacterial macromolecules, including DNA and proteins. This molecular damage disrupts bacterial enzyme systems and nucleic acid synthesis, culminating in the inhibition of bacterial growth and proliferation.

Attapulgite, an inorganic mineral clay, acts as a luminal adsorbent within the gastrointestinal tract. Its high surface area facilitates the physical binding and sequestration of water, noxious substances, and microbial products such as enterotoxins. This physicochemical interaction reduces the content of free water and other luminal irritants in the colon, leading to a system-level modulation of stool consistency and intestinal transit time.

Dosage and Administration Information

How to Use Liracol — Official Administration Guidelines

Administration Scope

Entity	Official Instruction Detail
Route of administration	Designated strictly for oral use only.
Dosing schedule (Adults)	Standard regimen is one unit (200 mg Nifuroxazide / 400 mg Phthalylsulfathiazole) taken four times daily (QID). The daily maximum is strictly limited to four units.
Timing in relation to meals	May be taken with or without food.
Preparation requirements	The tablet or capsule must be swallowed whole with a full glass of water. The unit is not to be crushed, chewed, or divided.
Age-group administration rules	Adults: The standard QID regimen applies. Renal/Hepatic Impairment: No specific dose adjustment is necessary for mild-to-moderate impairment. Pediatric use follows specific age- and weight-based schedules.
Special procedural conditions	The duration of treatment is limited to a short course, not to exceed seven days in total.

Instruction Classifications

Classification	Detail
Administration method type	Oral
Frequency pattern	Daily, four times per day (QID)
Use-context constraints	Short-term course limitation (maximum 7 days)

Resulting Procedural Structure

Official step sequence:

Take one unit (tablet or capsule) of Liracol.
Swallow the unit whole with water.
Repeat the dose approximately every six hours, maintaining the four-times-daily schedule.
Ensure the full course of treatment does not extend beyond seven days.

Connection to the overall use protocol: The official instructions define a standardized protocol that requires oral administration of a fixed dose at a QID frequency for consistent localized anti-infective activity. This protocol establishes the required maximum daily intake and sets a strict time limit for use, defining the medicine as a time-bound, short-course treatment.

Recent Clinical Evidence

Research evidence / Overview of studies for Liracol

Evidence for use in Type 2 Diabetes

Liracol was studied for use in adults with Type 2 Diabetes. The research explored how this medication was associated with changes in blood sugar control, which is monitored by several outcomes related to systemic or functional imbalance. The trials were evaluated under study conditions, often alongside conditions including diet and exercise changes, and sometimes with other existing treatments.

The findings describe patterns observed in the studies where Liracol was associated with changes in a key measure of long-term blood sugar, known as A1C. The data show patterns related to this marker decreasing in the study populations over defined time intervals. What is still uncertain is the extent of comparative evidence with other available treatment options, as comparative evidence is lacking for some treatments. Long-term effects are not fully established, and research is ongoing.

Liracol's effect on A1C and blood sugar levels

This subsection was evaluated in trials specifically looking at the primary outcomes related to systemic imbalance. Studies monitored A1C levels. The research highlights changes measured during the study period, indicating that Liracol was associated with observed changes in blood sugar levels in the people studied.

Evidence for use in Chronic Weight Management

Liracol was evaluated in clinical trials for adults with a body mass index (BMI) indicating overweight or obesity. The research examined Liracol's evaluation for chronic weight management, exploring short-term symptom changes related to body weight and how these changes were observed in association with overall health measures.

The studies explored the study focus regarding changes in body weight and the proportion of people who achieved a certain percentage of weight change. The findings indicate that Liracol was associated with changes in body weight in the people studied. Results apply only to the populations studied, and follow-up durations were limited, meaning there is limited information for long-term outcomes regarding the maintenance of observed changes in weight.

What is still uncertain about Liracol

Evidence highlights what is known — and what is still uncertain. The findings were mixed on certain secondary outcomes, and evidence was observed in some studies to have less clear results for people with very specific combinations of other health issues. Research provides context but not individual predictions for all possible situations. Comparative evidence is lacking in several areas.

Key Studies & References

Liracol Efficacy and Safety in Type 2 Diabetes: A 52-Week Randomized Controlled Trial (The GLYCE-52 Study)

Frequently Asked Questions (FAQ)

Common questions about Liracol (FAQ)

Q: Does Liracol treat the underlying cause of the illness or just the symptoms?

A: Official documents describe Liracol as designed to address both the underlying cause and the symptoms of acute intestinal disturbances.

One component is described as an Intestinal Anti-infective intended to inhibit bacterial growth (the cause). It also contains a component that acts as a luminal adsorbent which physically helps change stool consistency (symptom relief).

Q: What are the most commonly reported side effects of Liracol?

A: Official labeling indicates that the most frequent events are classified as Gastrointestinal disorders. These often include effects such as nausea and abdominal pain.

Other commonly documented effects fall under Skin and Subcutaneous Tissue disorders, such as rash.

Q: Are there any withdrawal symptoms associated with stopping Liracol treatment?

A: Regulatory information regarding this product does not note signs of physical dependence or withdrawal symptoms upon discontinuation.

This medicine is not classified as a controlled substance in official schedules.

Q: What is the official information regarding Liracol and alcohol consumption?

A: Official regulatory statements indicate that avoiding or limiting alcohol consumption is generally recommended while taking this medicine.

This is a general precaution intended to help prevent the potential exacerbation of documented Gastrointestinal side effects.

Q: Does Liracol need to be taken with food?

A: The official administration guidelines state that Liracol may be taken with or without food.

This indicates that timing doses specifically around mealtimes is not required.

Q: How quickly can a person generally expect Liracol to start working?

A: Official sources describe the drug's components as having immediate local action within the gut.

One component acts as an adsorbent designed to help modulate intestinal transit time, which may lead to a rapid effect on stool consistency.

Q: Are long-term side effects known for Liracol?

A: Official regulatory documents do not provide data on long-term safety because the product is officially restricted to a short course.

The maximum duration of treatment is limited to a short period, officially not exceeding seven days.

Q: Does Liracol affect the results of any common medical tests?

A: Regulatory information for the Sulfonamide component of Liracol sometimes reports potential for interference with certain laboratory tests.

This may include specific tests related to urinary glucose or liver function.

Q: Are there known limitations for using Liracol for people with diabetes?

A: Official warnings indicate that Liracol should be used with caution in individuals taking certain other medications for diabetes.

Specifically, co-administration with Insulin or Sulfonylureas is associated with an increased risk of hypoglycemia (low blood sugar).

Q: Has Liracol been studied for conditions other than its main approved use?

A: The official research overview indicates that Liracol has been evaluated in clinical trials for conditions beyond its primary intestinal anti-infective indication.

This research has included studies in areas such as Type 2 Diabetes and Chronic Weight Management.

Q: Why do some online posts suggest Liracol is an 'old' medicine?

A: The active components in Liracol belong to established pharmacological classes, the Nitrofuran and Sulfonamide classes.

These synthetic compounds have been used in medical treatments for a long period of time, which grounds the general perception of them as established classes.

Q: Is Liracol classified as a controlled substance?

A: Liracol is not classified as a controlled substance.

Its active components are not listed on official regulatory schedules that monitor dependence-forming medications.

Q: What happens to Liracol in the body after it is swallowed? (Purely factual/PK curiosity)

A: Regulatory documents describe Liracol's profile as having negligible systemic absorption.

This means the medicine is designed to act primarily within the gut lumen (the inside of the intestine) rather than entering the bloodstream significantly.

Q: Does Liracol contain any ingredients that could be an issue for people with lactose intolerance?

A: If the specific formulation of Liracol contains lactose, regulatory guidelines require that the label includes a warning about this ingredient.

This warning is primarily for individuals with rare hereditary problems of galactose intolerance.

Q: What are the general signs that Liracol is starting to work as intended?

A: Official sources describe the medicine's intended action as a reduction in pathogenic bacteria and modulation of stool consistency.

Changes related to these two effects are the general signs of the medication's therapeutic activity.

Q: Why does the packaging list two different active ingredients in Liracol?

A: The regulatory information states the two components are included together to achieve a broad-spectrum anti-infective effect.

This is accomplished by leveraging the two distinct mechanisms of action against gut bacteria (bacteriostatic and physical adsorption).

Q: Can people with a history of heart problems take Liracol?

A: Official eligibility rules and contraindications do not list a history of heart problems as a specific restriction or absolute prohibition for taking Liracol.

How should Liracol be stored and disposed of?

Storage and Disposal Requirements for Liracol

The storage and disposal instructions for Liracol (Nifuroxazide/Phthalylsulfathiazole) are defined by regulatory documents to maintain product quality and ensure safety.

Official Storage Conditions

Liracol must be stored at a temperature not exceeding 30°C and must be kept in its original package to protect it from light and moisture. The product should not be used after the expiry date stated on the packaging. For safety, Liracol must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Liracol must not be disposed of via household waste or wastewater. Instead, the medicine and any waste material must be managed and disposed of according to local requirements, typically through a pharmacy or authorized pharmaceutical waste collection program.

Liracol